Pella Pharmaceuticals Co. Ltd

Pella Pharmaceuticals Co. Ltd is a Manufacturer, Pharmaceutical Company, Research Institute in the Pharmaceuticals industry. It researches, develops, and delivers medicinal products — covering prescription drugs, OTC medicines, biologics, and specialty therapeutics. The company serves healthcare providers, hospital networks, retail pharmacies, and regulated distribution channels.

Pella Pharmaceuticals Co. Ltd has been operating since its founding. That experience reflects well-established R&D capabilities, deeper regulatory knowledge, and long-standing relationships with clinical partners and approved suppliers.

Pella Pharmaceuticals Co. Ltd is headquartered in Jordan. Operating location determines regulatory jurisdiction — US-based companies follow FDA frameworks, while others operate under EMA, WHO, or local health authority requirements.

Pella Pharmaceuticals Co. Ltd operates as a Manufacturer, Pharmaceutical Company, Research Institute. Innovator companies develop and patent new drug compounds; generic manufacturers produce off-patent formulations; distributors supply products to pharmacy, hospital, and clinical channels. Pella Pharmaceuticals Co. Ltd may operate across more than one of these roles.

Pella Pharmaceuticals Co. Ltd is led by Fadi M. Abu Ta’a, a key executive. Leadership in pharmaceuticals typically comes from clinical research, regulatory affairs, medicinal chemistry, or commercial strategy — backgrounds that directly influence pipeline decisions and market positioning.

Fadi M. Abu Ta’a serves as a key executive at Pella Pharmaceuticals Co. Ltd, responsible for drug development pipelines, regulatory submissions, quality assurance, and commercial growth across prescription and OTC channels.